These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 17387005)
1. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Sosabowski JK; Lee M; Dekker BA; Simmons BP; Singh S; Beresford H; Hagan SA; McKenzie AJ; Mather SJ; Watson SA Eur J Pharm Sci; 2007 Jun; 31(2):102-11. PubMed ID: 17387005 [TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353 [TBL] [Abstract][Full Text] [Related]
3. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. von Guggenberg E; Sallegger W; Helbok A; Ocak M; King R; Mather SJ; Decristoforo C J Med Chem; 2009 Aug; 52(15):4786-93. PubMed ID: 19591486 [TBL] [Abstract][Full Text] [Related]
4. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison. Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319 [TBL] [Abstract][Full Text] [Related]
5. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates. Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429 [TBL] [Abstract][Full Text] [Related]
6. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. Pawlak D; Rangger C; Kolenc Peitl P; Garnuszek P; Maurin M; Ihli L; Kroselj M; Maina T; Maecke H; Erba P; Kremser L; Hubalewska-Dydejczyk A; Mikołajczak R; Decristoforo C Eur J Pharm Sci; 2016 Mar; 85():1-9. PubMed ID: 26826279 [TBL] [Abstract][Full Text] [Related]
7. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. Reilly RM; Scollard DA; Wang J; Mondal H; Chen P; Henderson LA; Bowen BM; Vallis KA J Nucl Med; 2004 Apr; 45(4):701-8. PubMed ID: 15073268 [TBL] [Abstract][Full Text] [Related]
9. Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. Trejtnar F; Laznicek M; Laznickova A; Kopecky M; Petrik M; Béhé M; Schmidt J; Maecke H; Maina T; Nock B Anticancer Res; 2007; 27(2):907-12. PubMed ID: 17465219 [TBL] [Abstract][Full Text] [Related]
10. Targeting of cholecystokinin B/gastrin receptor in colonic, pancreatic and hepatocellular carcinoma cell lines. Savage K; Waller HA; Stubbs M; Khan K; Watson SA; Clarke PA; Grimes S; Michaeli D; Dhillon AP; Caplin ME Int J Oncol; 2006 Dec; 29(6):1429-35. PubMed ID: 17088981 [TBL] [Abstract][Full Text] [Related]
11. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945 [TBL] [Abstract][Full Text] [Related]
12. Formulation development and stability testing of oral morphine solution utilizing preformulation approach. Preechagoon D; Sumyai V; Tontisirin K; Aumpon S; Pongjanyakul T J Pharm Pharm Sci; 2005 Aug; 8(2):362-9. PubMed ID: 16124948 [TBL] [Abstract][Full Text] [Related]
13. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729 [TBL] [Abstract][Full Text] [Related]
14. The impact of primary packaging on the quality of parenteral products. Solomun L; Ibric S; Boltic Z; Djuric Z; Stupar B J Pharm Biomed Anal; 2008 Nov; 48(3):744-8. PubMed ID: 18786797 [TBL] [Abstract][Full Text] [Related]
16. Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial. André P; Cisternino S; Chiadmi F; Toledano A; Schlatter J; Fain O; Fontan JE Ann Pharmacother; 2005 Sep; 39(9):1462-6. PubMed ID: 15985470 [TBL] [Abstract][Full Text] [Related]
17. Stability studies of anticancer agent bis(4-fluorobenzyl)trisulfide and synthesis of related substances. Bao Y; Mo X; Xu X; He Y; Xu X; An H J Pharm Biomed Anal; 2008 Nov; 48(3):664-71. PubMed ID: 18678459 [TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of gastrin derivatives labelled with 111In: radiolabelling, affinity profile and pharmacokinetics in rats. Melicharova L; Laznickova A; Laznicek M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):544-51. PubMed ID: 24108197 [TBL] [Abstract][Full Text] [Related]